WO2025113470 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN (TTR)
National phase entry is expected:
Publication Number
WO/2025/113470
Publication Date
05.06.2025
International Application No.
PCT/CN2024/134773
International Filing Date
27.11.2024
Title **
[English]
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN (TTR)
[French]
COMPOSITIONS ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DE LA TRANSTHYRÉTINE (TTR)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
XIA, Shiwei
Priority Data
PCT/CN2023/134234
27.11.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4170 | |
| EPO | Filing, Examination, Granting | 66452 | |
| Japan | Filing, Examination, Granting | 4124 | |
| South Korea | Filing, Examination, Granting | 6003 | |
| USA | Filing, Examination, Granting | 21790 |
Total:
102,539
Contact Us
Abstract[English]
Compositions and methods useful to reduce expression of TTR gene and for treatment of TTR-associated diseases and conditions are provided. Provided are TTR dsRNA agents, TTR antisense polynucleotide agents, compositions comprising TTR dsRNA agents, and compositions comprising TTR antisense polynucleotide agents that can be used to reduce TTR expression in cells and subjects.[French]
La présente invention concerne des compositions et des procédés utiles pour réduire l'expression du gène TTR et pour le traitement de maladies et d'affections associées au gène TTR. La présente invention concerne des agents ARNdb de la TTR, des agents polynucléotides antisens de la TTR, des compositions comportant des agents ARNdb de la TTR et des compositions comportant des agents polynucléotides antisens de la TTR, pouvant être utilisés pour réduire l'expression de la TTR dans des cellules et chez des sujets.